Background: Metabolic pathways that give rise to functional decline and mobility disability in older adults are incompletely understood. Methods: To identify metabolic perturbations that may affect functional decline, nontargeted metabolomics was used to measure 350 metabolites in baseline plasma from 313 black men in the Health ABC Study (median age 74 years). Usual gait speed was measured over 20 m. Cross-sectional relationships between gait speed and metabolites were explored with partial correlations adjusted for age, study site, and smoking status. Risk of incident mobility disability (two consecutive reports of severe difficulty walking quarter mile or climb 10 stairs) over 13 years of follow-up was explored with Cox regression models among 307 men who were initially free of mobility disability. Significance was determined at p ≤ .01 and q (false discovery rate) ≤ 0.30. Results: Two metabolites were correlated with gait speed: salicylurate (r = −.19) and 2-hydroxyglutarate (r = −.18). Metabolites of amino acids and amino acid degradation (indoxy sulfate; hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.09-2.03, symmetric dimethylarginine; HR = 3.58, 95% CI = 1. 57-8.15, N-carbamoyl beta-alanine; HR = 1.91, 95% CI = 1.16-3.14, quinolinate; HR = 2.56, 95% CI = 1.65-3.96) and metabolites related to kidney function (aforementioned symmetric dimethylarginine and indoxy sulfate as well as creatinine; HR = 5.91, 95% CI = 2.06-16.9, inositol; HR = 2.70, 95% CI = 1.47-4.97) were among the 23 metabolites associated with incident mobility disability. Conclusions: This study highlights the potential role of amino acid derivatives and products and kidney function early in the development of mobility disability and suggests metabolic profiles could help identify individuals at risk of functional decline.
as proximal on the pathway to disability. Increasingly, performance measures such as gait speed, which can be considered functional limitations (5) , are measured in research and clinical settings to supplement self-report of disability. Therefore, performance measures, and particularly gait speed, have been extensively studied as potential measures to identify older adults at risk of mobility disability (5, 6) .
A considerable number of potentially modifiable risk factors for mobility disability such as age-related diseases, functional limitations, sedentary lifestyles (7) , and excess body weight (8) have been identified. There is, however, conflicting or limited evidence on the relative importance of various risk factors, mechanisms linking risk factors, and potential targets for interventions. Increased understanding of mechanisms underlying mobility disability and the disablement process is thus critically needed to address this public health concern.
Metabolomics is the study of endogenous and exogenous small molecules that participate in metabolism. Metabolomics platforms can provide molecular data on many of the standard biomarkers in epidemiological studies (eg, insulin and cholesterol) in addition to several hundred metabolites. Metabolomics has the potential to identify biomarkers of early unrecognized multimorbidity including diabetes (9) and cancer (10) or biomarkers linked to muscle function (11) , which are each known to be underpinnings of mobility disability. To date, investigation of metabolic correlates of physical function has been limited to two studies: one in functionally limited older adults participating in a nutritional supplementation and exercise intervention (11) and one focused on exploration of acylcarnitines and physical function in older men (12) . The metabolic correlations of mobility disability in older adults have yet to be studied. There is a particular need for increased understanding of mobility disability among black older adults, who have a higher prevalence of mobility disability than other ethnic groups (2) . Therefore, the aim of this study is to provide insight into relationships between human metabolism and physical function. To accomplish this, we explored metabolic correlates of gait speed and development of incident mobility disability over 13 years of follow-up. As gait speed is a measure of physical performance and possibly an earlier process in the pathway to disability, differences in metabolic correlates between the two measures were expected.
Methods

Population
The Health, Aging and Body Composition (Health ABC) Study is a prospective, longitudinal study of 3,075 community-dwelling, black and white men and women aged 70-79 years. Participants were recruited from a random sample of white Medicare beneficiaries in selected zip codes and all black Medicare-eligible residents in the Memphis, TN, and Pittsburgh, PA areas. All participants initially reported no reported difficulty walking one quarter of a mile, climbing 10 steps without resting or performing activities of daily living, had no active treatment for cancer in the prior 3 years, intended to stay in the study area for at least 3 years, and had no active participation in a lifestyle intervention trial.
For this analysis, a random sample of 319 black men was selected from participants at the year 2 study visit as detailed previously (13) . Gait speed was missing for N = 6, resulting in a population of N = 313. For the analysis of incident mobility disability, six participants were excluded because of development of mobility disability between baseline and the year 2 study visit.
Physical Function
Two indicators of function were explored to provide a more complete characterization in relation to metabolomics. Gait speed, an objective assessment of performance, provides an opportunity to characterize cross-sectional relationships between function and metabolites prior to mobility disability. Mobility disability, a subjective assessment, provides an opportunity to examine prospective relationships between function and metabolites.
Gait speed was measured from usual walking pace over 20 m. Timing was started with the first footfall and was stopped after the first footfall crossed the end line (14) . Mobility disability was defined using accepted self-reported measures of physical function (15, 16) : two consecutive reports of having severe difficulty walking quarter mile or climbing 10 steps. Reports involved the same function (ie, two reports of severe difficulty walking a quarter mile or two reports of severe difficulty climbing stairs). Participants reported physical function during annual visits and telephone interviews every 6 months. If participants reported severe difficulty at a visit but were deceased before the next 6-month contact, mobility difficulty was presumed to persist until death, and the participant was classified with mobility disability. Time to event or censorship was calculated from the date of the year 2 visit to the date of the first report of difficulty or last completed contact. If participants missed a study visit, target dates for when the visit should have been completed were used to calculate time to event (14, 17) .
Metabolite Profiling
A total of 350 metabolites were measured using the metabolite-profiling platform of the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Methodologies have been described previously (13, 18) . Briefly, polar metabolites and lipids in plasma extracts were measured with three liquid chromatographymass spectroscopy (LC-MS) methods. Lipids were analyzed using a Nexera X2 U-HPLC (Shimadzu, Marlborough, MA) coupled to an Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific; Waltham, MA). Plasma extracts (2 µL) were injected onto an ACQUITY UPLC BEH C8 column (1.7 µm, 2.1 × 100 mm; Waters; Milford, MA). The column was initially eluted isocratically at a flow rate of 450 µL/min with 80% mobile phase A (95:5:0.1 vol/vol/vol 10 mM ammonium acetate/methanol/formic acid) for 1 minute followed by a linear gradient to 80% mobile phase B (99.9:0.1 vol/vol methanol/formic acid) over 2 minutes, a linear gradient to 100% mobile phase B over 7 minutes, then 3 minutes at 100% mobile phase B. MS analyses used electrospray ionization in the positive-ion mode (source voltage was 3 kV, source temperature was 300°C, sheath gas was 50.0, auxiliary gas was 15) and full-scan analysis over m/z 200-1100 and at 70,000 resolution. Hydrophilic interaction liquid chromatography (HILIC) analyses of water-soluble metabolites were conducted in the positive-ion mode using a Nexera X2 U-HPLC (Shimadzu, Marlborough, MA)-Q Exactive Orbitrap (Thermo Fisher Scientific; Waltham, MA) LC-MS instrument. Plasma samples (10 µL) were extracted using 90 µL of 74.9:24.9:0.2 vol/vol/ vol acetonitrile/methanol/formic acid containing stable isotopelabeled internal standards (valine-d8, Isotec; and phenylalanined8, Cambridge Isotope Laboratories; Andover, MA). Samples were centrifuged (10 minutes, 9,000g, 4°C), and the supernatants were injected directly onto a 150 × 2 mm Atlantis HILIC column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 250 µL/min with 5% mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 1 minute followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes. The electrospray ionization voltage was 3.5 kV and data were acquired using full-scan analysis over m/z 70-800 at 70,000 resolution. HILIC analyses of water-soluble metabolites in the negative-ion mode were acquired using an ACQUITY UPLC (Waters) coupled with a 5500 QTRAP triple quadrupole MS (AB SCIEX) as described previously (18) .
Progenesis CoMet (Nonlinear Dynamics) and TraceFinder 3.1 (Thermo Fisher Scientific) software were used to integrate LC-MS peaks in data generated using Orbitrap MS systems. MultiQuant 2.1 software (SCIEX) was used to automatically integrate 55000 QTRAP data and for manual review of data quality (19) . Chromatographic retention times were determined from reference standards for each metabolite. Metabolite identity was determined by comparison of peaks with known standards. Metabolite signals were measured as LC-MS peak areas proportional to metabolite concentrations. The median intraclass correlation coefficient across 350 metabolites was .92, and the interquartile range was 0.81-0.97, indicating a high level of reliability.
Statistical Analysis
Metabolites were skewed and were log-transformed to approximate a normal distribution. Metabolites were grand mean centered to a mean of 0 and a variance of 1. Missing metabolites were assumed to be below the limit of detection and imputed with half of the minimum value of the non-missing metabolite.
The study was designed to be hypothesis generating, and thus, Pearson partial correlations between metabolites and gait speed were minimally adjusted for covariables expected to have large influences one metabolites and interpretation including measured weight change in the year prior to metabolite measurement, age, study site, and smoking status. Post hoc analysis correlations were conducted to aid in the interpretation of findings. Glucuronate plays a role in the clearance of some drugs and toxins (20) and was correlated to total number of prescription medications. Salicylurate, a conjugate formed to eliminate excess salicylates such as aspirin, was correlated to use of salicylate medications. Homogentisate and hydroxyphenylacetate are intermediates in the metabolic breakdown of tyrosine and phenylalanine (20) . As tyrosine and phenylalanine are altered in states of protein degradation (21) , weight change was explored in relation to homogentisate and hydroxyphenylacetate.
Cox proportional hazards regression was used to calculate multivariable-adjusted (age, study site, smoking status) hazard ratios (HR) of incident mobility disability and 95% confidence intervals (CI). Gait speed is a strong predictor of mobility disability (5, 22) ; thus, post hoc adjustment for year 2 gait speed was conducted to provide insight on which metabolites are markers of mobility disability (eg, attenuation of HR with adjustment) versus those that may have causal implications. Time from the year 2 visit to study exit (mobility disability or censoring) was the underlying time scale for each participant. The proportional hazards assumption was tested using Schoenfeld residuals and met for all variables. To account for multiple comparisons, false discovery rates were computed with use of the q value method and the bootstrap method for estimating the overall proportion of true null hypotheses. Significance levels in prior exploratory analyses (11, 23, 24) guided the choice of statistical significance in this study, which was set at p ≤ .01 and q ≤ 0. 
Results
Characteristics of the sample of 313 participants are shown in Table 1 . The mean (SD) age of the sample was 74.6 years. Participants predominantly had less than a high school education, were likely to have reported current or former smoking, had prevalent disease, and low levels of physical activity. The mean body mass index was overweight. The mean gait speed was 1.10 m/s and 26% had gait speed below 1.0 m/s, a level associated with reduced survival (25, 26) .
Seven metabolites correlated with gait speed at p ≤ .01 are shown in Table 2 along with the metabolite taxonomy super and subclass. Of these, four were lipids and lipid-like molecules, two were benzenoids, and one was an organooxygen compound. Only two metabolites were correlated at p ≤ .01 and q ≤ 0.30, 2-hydroxyglutarate (r = −.17) and salicylurate (r = −.19), the remaining five metabolites did not meet the q value threshold. Post hoc analysis showed an r = .34 (p < .0001) between glucuronate and the number of prescription medications and an r = .47 (p < .0001) between salicylurate metabolite levels and use of salicylate medications. Homogentisate (r = .02, p = .77) and hydroxyphenylacetate (r = .02, .71) were not correlated with weight change in the prior year (mean [SD] change = −0.31 kg [3.37] ).
Over a median (SE) follow-up of 8.1 (0.23) years (total person years = 2,489), 120 participants developed incident mobility disability. Associations between metabolites and incident mobility disability are shown in Table 3 along with the metabolite taxonomy super and subclass. Twenty-three metabolites were associated with incident mobility disability. All metabolites were positively associated with risk except three lipids; C38:2 phosphatidylethanolamine (PE), C18:2 cholesterol ester, and C36:4 phosphatidylcholine A. Of the 23 metabolites, 11 were lipids and lipid-like metabolites; five were organic acids and derivatives; three were organoheterocyclic 
Discussion
This study adds to the evidence on metabolites in relation to gait speed (11, 12) and contributes new evidence on associations between metabolites with incident mobility disability. In this population of older black men, gait speed was correlated with two metabolites, whereas incident mobility disability was uniquely associated with 23 metabolites, respectively. After adjustment for year 2 gait speed, nine metabolites (5-aminolevulinic acid, sdma, hypoxanthine, quinolinate, creatinine, butyrobetaine, C3 carnitine, inositol, and C36:1 PS plasmalogen) remained associated with mobility disability. This suggests these metabolites do not simply reflect subclinical mobility disability and may be important biomarkers for future mobility disability. Note: CE = cholesterol ester; CI = confidence interval; HR = hazard ratio; PC = phosphatidylcholine; PE = phosphatidylethanolamine; PS = phosphatidylserine; sdma = symmetric dimethylarginine. Taxonomy classes based on HMDB 3.0 (20) . HR adjusted for age, study site, smoking, and prior weight change.
Plasma Metabolites Significantly Correlated With Gait Speed
The main results of this study show that only two metabolites, salicylurate and 2-hydroxyglutarate, are inversely correlated with gait speed. 2-Hydroxyglutarate has been identified as an oncometabolite (27) . Salicylurate is formed by the body to eliminate excess salicylates, namely aspirin, and is thus strongly correlated with aspirin use. Therefore, we hypothesize that relationships between gait speed and metabolites reflect the increased prevalence of chronic disease and thus probably medications in those with low gait speed. Only one of the prior studies of metabolomics and gait speed measured 2-hydroxyglutarate and did not find significant associations between gait speed and 2-hydroxyglutarate (11) . They also reported a number of significant associations between gait speed and metabolites indicative of gut microbial metabolism, peroxisome proliferator-activated receptor-α activation, and insulin activity. It is important to note that although both populations were older, other measures differed. Our population did not have mobility disability at the time of gait speed measurement and completed a 20-m walk test, whereas those in Lustgarten and colleagues were functionally limited and completed a 400-m walk test, which would be more likely to capture endurance. Although our sample size was larger than the previous study, it is possible that the general lack of correlations in this study reflects the small sample or relatively small variation in gait speed (SD 0.20).
Plasma Metabolites Significantly Associated With Incident Mobility Disability
Findings for creatinine, N-carbamoyl beta-alanine, sdma, quinolinate, inositol, inosine, hypoxanthine and indoxyl sulfate suggest a possible main role for kidney function in development of mobility disability among older adults. Serum creatinine is a marker of kidney function (28) . Elevated N-carbamoyl beta-alanine suggests increased carbamylation, a posttranslational protein modification that is mediated by a urea by-product. Carbamylation increases with kidney function decline (29) . Elevated sdma occurs in patients with vascular disease and renal disease (30) . Quinolinate and inositol metabolites have been positively associated with incident chronic kidney disease (31) . Inosine and hypoxanthine are known uremic toxins (32) . Indoxyl sulfate is a circulating uremic toxin that stimulates glomerular sclerosis and interstitial fibrosis in the kidney (33) . Indoxyl sulfate accelerates the progression of kidney failure (34) . Plasma levels of short-chain acylcarnitine were greater among patients with chronic uremia compared with healthy controls (35) , and there is some suggestion that the lipid metabolites in our study may also play a role in kidney function as the amount of total phosphatidylcholine is increased in plasma of uremic patients (36) .
Altered kidney function could lead to mobility disability in a number of indirect and direct ways. Chronic kidney disease shares risk factors with mobility limitations including lower socioeconomic status, lower physical activity, and increased rates of cardiovascular disease and cerebrovascular disease (37) . Chronic low-grade inflammation, metabolic acidosis and chronic hyperglycemia have important roles in the pathogenesis of chronic kidney disease (38) . These factors also influence protein turnover and can lead to loss of lean mass and strength, which would increase the risk for development of mobility disability. In support of this, a study in younger adults reported that uremia-related metabolites are associated with lean mass (39) . Furthermore, hydroxyproline, a marker of muscle damage (40) , was associated with mobility disability in the current study. As well, quinolinate and 5-aminolevulinic acid are associated with inflammation and innate immunity (41, 42) ; pathogenic factors Note: CI = confidence interval; HR = hazard ratio; PC = phosphocholine; PE = phosphatidylethanolamine; PS = phosphatidylserine; sdma = symmetric dimethylarginine. Taxonomy classes based on HMDB 3.0 (20) . HR adjusted for age, study site, smoking, prior weight change, and year 2 gait speed.
for chronic kidney disease, further supporting a role for mechanisms related to kidney function. Collectively, these data suggest a role for kidney function on development of mobility disability, although the mechanisms need to be investigated further.
Associations between creatinine, N-carbamoyl beta-alanine, 5-aminolevulinic acid, quinolinate, indoxyl sulfate, hydroxyproline, and sdma with mobility disability suggest a role for amino acid metabolism and degradative pathways on development of mobility disability. However, many of these metabolites also play a role in kidney function, and it is thus difficult to disentangle the separate role for mechanisms related to amino acid metabolism and degradation and kidney function on influencing mobility disability.
Overall, 12 lipids, including four PE species, butyrobetaine, a precursor of L-carnitine, and four metabolites of carnitine were associated with mobility disability. Plasmalogens are considered to be sensitive markers of oxidative stress (43) . Our finding of positive associations between two plasmalogen metabolites and mobility disability is supported by previous studies that show oxidative damage is a risk factor for both mobility disability (44) and kidney disease (43) . The positive associations between acylcarnitine levels and mobility disability align with prior evidence of elevated acetylcarnitine in older men with lower physical performance (12) . Carnitine is the carrier moiety of acylcarnitines and plays an essential role in mitochondrial metabolism and muscle bioenergetics (45) . In conditions of diminished carnitine bioavailability, for example, decreased dietary intake, altered biosynthesis or expenditure, an accumulation of acylcarnitine intermediates may occur. We hypothesize that elevated acylcarnitine metabolites indicate reduced carnitine and may contribute to processes related to muscle loss and function, earlier processes in the disablement pathway. In support of our hypothesis, supplementation with carnitine in older adults has been shown to increase muscle mass (46) and mitigate metabolic stress and muscle damage after exercise in middle-aged adults (45) . Experimental evidence suggests that PE inhibits mitochondrial bioenergetics function (47) . Evidence also suggests that aging may be accompanied by changes in skeletal muscle mitochondrial function that affects the capacity of skeletal muscle cells to adapt to physiological stress (48) . It is possible that PE species contribute to the age-related changes in skeletal muscle mitochondria and affect mobility disability through muscle related pathways. However, studies that specifically address this hypothesis in humans are lacking.
A strength of the study is the use of two measures related to physical function; gait speed, an early indicator of decline in function, and incident mobility disability over more than a decade of follow-up. This enabled us to identify metabolites that may be important effectors or markers of subsequent functional decline. Close surveillance of participants with serial queries about mobility ensured reliable ascertainment of mobility disability. There are also limitations to our study. Our population, though reasonable for a metabolomics study, is small for an epidemiological study. Results need to be validated and replicated. Despite the limited size, we identified metabolites robustly correlated with physical function. Second, the study population consisted of black men, and results may not be generalizable to women, younger populations or different race/ethnicities. However, previous metabolic studies have replicated associations between metabolites and phenotypes [eg, body mass index and amino acid metabolites (13, 49, 50) ] across populations composed of men and women with diverse race/ethnicities and demographics, suggesting some biological/physiological variations may have minimal impact on metabolite relationships. Metabolites were measured at only one time point, whereas follow-up for mobility disability occurred over a 13-year period. Serial measurement of metabolites would provide information on long-term concentrations. However, a prior study, which measured serum metabolite concentrations 4 months apart, reported reliable metabolite concentrations and concluded a single measurement reflects long-term metabolite concentrations (51) . As well, disablement is a process. Impairments and functional limitations precede the eventual outcome of disability (4), and thus, it is reasonable to assume that metabolic pathways are altered prior to participants reporting mobility disability.
Conclusion
Metabolites of kidney function were strongly, potentially, causally related to future mobility disability in this population of older black men. This supports evidence from clinical and observational studies on the role of kidney function on pathogenesis of mobility disability. Larger studies are warranted to determine if kidney function is a main pathway leading to incident mobility disability. The utility of these metabolites, particularly the 10 metabolites that were associated with mobility disability risk independent of gait speed, for early detection of mobility disability needs further investigation. Nonetheless, this study is a first step to a better biological understanding of physical function in older adult and identifying biomarkers to facilitate targeted care.
